Excipient stabilization of polypeptides treated with organic solvents

• US 5,589,167 A
• Filed: 04/08/1994
• Issued: 12/31/1996
• Est. Priority Date: 02/23/1993
• Status: Expired due to Term

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Cleland, Jeffrey L., Jones, Andrew J. S.
• Primary Examiner(s): Sayala, Chhaya D.
• Application Number:
  US08/256,187
• Time in Patent Office: 998 Days
• Field of Search: 424/85.7, 514/21, 530/351, 530/399
• US Class Current: 424/85.7
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

Methods for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with trehalose, a polyol having a molecular weight less than about 70,000 kD.

Claims

1. A method of stabilizing a polypeptide against denaturation in an organic solvent when treated with the organic solvent, wherein the method comprises admixing the polypeptide with a polyol, wherein the molecular weight of the polyol is less than about 70,000 kD and is trehalose, to form an admixture;

and treating the admixture with the organic solvent.

2. The method of claim 1, wherein the polypeptide is growth hormone.

3. The method of claim 2, wherein the growth hormone is human.

4. The method of claim 1, wherein the polypeptide is gamma interferon.

5. The method of claim 1, wherein the organic solvent is methylene chloride.

6. The method of claim 1, wherein the organic solvent is ethyl acetate.

7. The method of claim 1 wherein the polypeptide is dry.

8. The method of claim 7 wherein the polypeptide is lyophilized.

9. The method of claim 1 wherein the mass ratio of trehalose to polypeptide is from 100:

1 to 1;

100.

10. The method of claim 1 wherein the mass ratio of trehalose to polypeptide is from 1:

1 to 1;

10.

11. The method of claim 1 wherein the mass ratio of trehalose to polypeptide is from 1:

3 to 1;

4.

12. A method of formulating a polypeptide using a denaturing organic solvent comprising

a) admixing the polypeptide in an aqueous solution with a polyol having a molecular weight less than about 70,000 kD, wherein the polyol is trehalose;

and

b) treating the polypeptide in the aqueous solution with the organic solvent.

13. The method of claim 12, wherein the product of step a) is dried and reconstituted in an aqueous formulation.

14. The method of claim 12 further comprising formulating the polypeptide for controlled release.

15. A method of formulating a dry polypeptide for controlled release using a denaturing organic solvent comprising

a) admixing the polypeptide with an excipient, wherein said excipient is a polyol having a molecular weight less than about 70,000 kD, and the polyol is trehalose;

and

b) treating the product of step a) with the organic solvent.

16. The method of claim 15, further comprising encapsulation of the polypeptide in a polymer matrix.